Compile Data Set for Download or QSAR
Report error Found 27970 for UniProtKB: O60674
TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50300196(atropisomer 2 | atropisomer 1 | 10-(4-hydroxypheny...)
Affinity DataKi:  0.00100nMAssay Description:Inhibition of recombinant JAK2More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2010
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM113220(US8633206, 139)
Affinity DataIC50: 0.00405nMpH: 7.4Assay Description:A peptide mobility shift assay was used to quantify the phosphorylation of the JAKtide (JAK2 and JAK3) or the IRS-1 peptide (JAK1 and Tyk2). Reaction...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2014
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM113219(US8633206, 138)
Affinity DataIC50: 0.00767nMpH: 7.4Assay Description:A peptide mobility shift assay was used to quantify the phosphorylation of the JAKtide (JAK2 and JAK3) or the IRS-1 peptide (JAK1 and Tyk2). Reaction...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2014
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM112541(US8618103, I-37)
Affinity DataIC50: 0.00890nMpH: 7.2Assay Description:The kinase activity of all three JAK kinases is measured using a radioactive, end-point assay and with trace amounts of 33P-ATP. More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2014
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM112517(US8618103, I-13)
Affinity DataIC50: 0.0106nMpH: 7.2Assay Description:The kinase activity of all three JAK kinases is measured using a radioactive, end-point assay and with trace amounts of 33P-ATP. More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2014
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM112515(US8618103, I-11)
Affinity DataIC50: 0.0108nMpH: 7.2Assay Description:The kinase activity of all three JAK kinases is measured using a radioactive, end-point assay and with trace amounts of 33P-ATP. More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2014
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM333145(US10196393, Example 8-23 | (S)-(3-(dimethylamino)-...)
Affinity DataKi:  0.0130nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/26/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM333122(US10196393, Example 8 | US10196393, Example 8-15 |...)
Affinity DataKi:  0.0130nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM333144(US10196393, Example 8-22 | (S)-(3-(dimethylamino)a...)
Affinity DataKi:  0.0130nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM333144(US10196393, Example 8-22 | (S)-(3-(dimethylamino)a...)
Affinity DataKi:  0.0130nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/26/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM333122(US10196393, Example 8 | US10196393, Example 8-15 |...)
Affinity DataKi:  0.0130nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/26/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM333145(US10196393, Example 8-23 | (S)-(3-(dimethylamino)-...)
Affinity DataKi:  0.0130nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM333120(US10196393, Example 2 | (S)-(3-(dimethylamino)azet...)
Affinity DataKi:  0.0160nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/26/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM333121(US10196393, Example 4 | (S)-(3-(dimethylamino)azet...)
Affinity DataKi:  0.0160nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/26/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM473568(US10844057, Example 11 | US10947229, Example 4 | U...)
Affinity DataKi:  0.0160nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM350089(US10208040, Example 1 | ((S)-2-(6-(2-ethyl-5-fluor...)
Affinity DataKi:  0.0160nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM333120(US10196393, Example 2 | (S)-(3-(dimethylamino)azet...)
Affinity DataKi:  0.0160nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM333120(US10196393, Example 2 | (S)-(3-(dimethylamino)azet...)
Affinity DataKi:  0.0160nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM350089(US10208040, Example 1 | ((S)-2-(6-(2-ethyl-5-fluor...)
Affinity DataKi:  0.0160nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM473568(US10844057, Example 11 | US10947229, Example 4 | U...)
Affinity DataKi:  0.0160nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM473568(US10844057, Example 11 | US10947229, Example 4 | U...)
Affinity DataKi:  0.0160nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/26/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM333120(US10196393, Example 2 | (S)-(3-(dimethylamino)azet...)
Affinity DataKi:  0.0160nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM333121(US10196393, Example 4 | (S)-(3-(dimethylamino)azet...)
Affinity DataKi:  0.0160nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM113216(US8633206, 135)
Affinity DataIC50: 0.0165nMpH: 7.4Assay Description:A peptide mobility shift assay was used to quantify the phosphorylation of the JAKtide (JAK2 and JAK3) or the IRS-1 peptide (JAK1 and Tyk2). Reaction...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2014
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM112601(US8618103, I-97)
Affinity DataIC50: 0.0172nMpH: 7.2Assay Description:The kinase activity of all three JAK kinases is measured using a radioactive, end-point assay and with trace amounts of 33P-ATP. More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2014
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM112516(US8618103, I-12)
Affinity DataIC50: 0.0191nMpH: 7.2Assay Description:The kinase activity of all three JAK kinases is measured using a radioactive, end-point assay and with trace amounts of 33P-ATP. More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2014
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM112574(US8618103, I-70)
Affinity DataIC50: 0.0196nMpH: 7.2Assay Description:The kinase activity of all three JAK kinases is measured using a radioactive, end-point assay and with trace amounts of 33P-ATP. More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2014
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM113214(US8633206, 133)
Affinity DataIC50: 0.0199nMpH: 7.4Assay Description:A peptide mobility shift assay was used to quantify the phosphorylation of the JAKtide (JAK2 and JAK3) or the IRS-1 peptide (JAK1 and Tyk2). Reaction...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2014
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM333120(US10196393, Example 2 | (S)-(3-(dimethylamino)azet...)
Affinity DataKi:  0.0200nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM350090(US10208040, Example 3 | ((S)-3-(dimethylamino)pyrr...)
Affinity DataKi:  0.0200nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM350089(US10208040, Example 1 | ((S)-2-(6-(2-ethyl-5-fluor...)
Affinity DataKi:  0.0200nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM350092(US10208040, Example 6 | ((S)-2-(6-(2-ethyl-5-fluor...)
Affinity DataKi:  0.0200nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM473566(US10844057, Example 9 | US10947229, Example 2 | US...)
Affinity DataKi:  0.0200nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM350089(US10208040, Example 1 | ((S)-2-(6-(2-ethyl-5-fluor...)
Affinity DataKi:  0.0200nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/21/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM350090(US10208040, Example 3 | ((S)-3-(dimethylamino)pyrr...)
Affinity DataKi:  0.0200nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM333122(US10196393, Example 8 | US10196393, Example 8-15 |...)
Affinity DataKi:  0.0200nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/26/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM333120(US10196393, Example 2 | (S)-(3-(dimethylamino)azet...)
Affinity DataKi:  0.0200nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM350092(US10208040, Example 6 | ((S)-2-(6-(2-ethyl-5-fluor...)
Affinity DataKi:  0.0200nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM350089(US10208040, Example 1 | ((S)-2-(6-(2-ethyl-5-fluor...)
Affinity DataKi:  0.0200nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/9/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM350090(US10208040, Example 3 | ((S)-3-(dimethylamino)pyrr...)
Affinity DataKi:  0.0200nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM473566(US10844057, Example 9 | US10947229, Example 2 | US...)
Affinity DataKi:  0.0200nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/26/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM350090(US10208040, Example 3 | ((S)-3-(dimethylamino)pyrr...)
Affinity DataKi:  0.0200nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/9/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM473566(US10844057, Example 9 | US10947229, Example 2 | US...)
Affinity DataKi:  0.0200nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM333120(US10196393, Example 2 | (S)-(3-(dimethylamino)azet...)
Affinity DataKi:  0.0200nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2020
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM333122(US10196393, Example 8 | US10196393, Example 8-15 |...)
Affinity DataKi:  0.0200nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM350090(US10208040, Example 3 | ((S)-3-(dimethylamino)pyrr...)
Affinity DataKi:  0.0200nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/21/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM350090(US10208040, Example 3 | ((S)-3-(dimethylamino)pyrr...)
Affinity DataKi:  0.0200nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2020
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM333120(US10196393, Example 2 | (S)-(3-(dimethylamino)azet...)
Affinity DataKi:  0.0200nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/16/2019
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM350089(US10208040, Example 1 | ((S)-2-(6-(2-ethyl-5-fluor...)
Affinity DataKi:  0.0200nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/19/2020
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vertex Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM112569(US8618103, I-65)
Affinity DataIC50: 0.0201nMpH: 7.2Assay Description:The kinase activity of all three JAK kinases is measured using a radioactive, end-point assay and with trace amounts of 33P-ATP. More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2014
Entry Details
US Patent

Displayed 1 to 50 (of 27970 total ) | Next | Last >>
Jump to: